110 related articles for article (PubMed ID: 32778411)
1. Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors.
Partelli S; Landoni L; Andreasi V; Nessi C; Muffatti F; Crippa S; Cingarlini S; Bassi C; Falconi M
Surgery; 2020 Nov; 168(5):816-824. PubMed ID: 32778411
[TBL] [Abstract][Full Text] [Related]
2. Patterns of Recurrence after Resection for Pancreatic Neuroendocrine Tumors: Who, When, and Where?
Marchegiani G; Landoni L; Andrianello S; Masini G; Cingarlini S; D'Onofrio M; De Robertis R; Davì M; Capelli P; Manfrin E; Amodio A; Paiella S; Malleo G; Damoli I; Miotto M; Bianchi B; Nessi C; Vivani E; Scarpa A; Salvia R; Bassi C
Neuroendocrinology; 2019; 108(3):161-171. PubMed ID: 30481765
[TBL] [Abstract][Full Text] [Related]
3. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
4. A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors.
Genç CG; Jilesen AP; Partelli S; Falconi M; Muffatti F; van Kemenade FJ; van Eeden S; Verheij J; van Dieren S; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg; 2018 Jun; 267(6):1148-1154. PubMed ID: 28594340
[TBL] [Abstract][Full Text] [Related]
5. Treatment of locoregional recurrence after intentional curative resection of pancreatic cancer.
Menke-Pluymers MB; Klinkenbijl JH; Tjioe M; Jeekel J
Hepatogastroenterology; 1992 Oct; 39(5):429-32. PubMed ID: 1459525
[TBL] [Abstract][Full Text] [Related]
6. Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis.
Andreasi V; Ricci C; Partelli S; Guarneri G; Ingaldi C; Muffatti F; Crippa S; Casadei R; Falconi M
J Endocrinol Invest; 2022 Apr; 45(4):705-718. PubMed ID: 34773595
[TBL] [Abstract][Full Text] [Related]
7. Management of isolated recurrence after surgery for pancreatic adenocarcinoma.
Kim YI; Song KB; Lee YJ; Park KM; Hwang DW; Lee JH; Shin SH; Kwon JW; Ro JS; Kim SC
Br J Surg; 2019 Jun; 106(7):898-909. PubMed ID: 31162655
[TBL] [Abstract][Full Text] [Related]
8. Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years.
Desai GS; Pande P; Chhabra V; Shah RC; Jagannath P
Indian J Gastroenterol; 2019 Oct; 38(5):399-410. PubMed ID: 31802438
[TBL] [Abstract][Full Text] [Related]
9. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
10. Nonfunctioning neuroendocrine pancreatic tumors: our experience and management.
Nomura N; Fujii T; Kanazumi N; Takeda S; Nomoto S; Kasuya H; Sugimoto H; Yamada S; Nakao A
J Hepatobiliary Pancreat Surg; 2009; 16(5):639-47. PubMed ID: 19365596
[TBL] [Abstract][Full Text] [Related]
11. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy.
Postlewait LM; Ethun CG; Baptiste GG; Le N; McInnis MR; Cardona K; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK
J Surg Oncol; 2016 Sep; 114(4):440-5. PubMed ID: 27334541
[TBL] [Abstract][Full Text] [Related]
13. The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms.
Partelli S; Javed AA; Andreasi V; He J; Muffatti F; Weiss MJ; Sessa F; La Rosa S; Doglioni C; Zamboni G; Wolfgang CL; Falconi M
Eur J Surg Oncol; 2018 Jun; 44(6):778-783. PubMed ID: 29610023
[TBL] [Abstract][Full Text] [Related]
14. Are Cystic Pancreatic Neuroendocrine Tumors an Indolent Entity Results from a Single-Center Surgical Series.
Paiella S; Marchegiani G; Miotto M; Malpaga A; Impellizzeri H; Montagnini G; Pollini T; Nessi C; Butturini G; Capelli P; Posenato I; Scarpa A; D'Onofrio M; De Robertis R; Cingarlini S; Boninsegna L; Bassi C; Salvia R; Landoni L
Neuroendocrinology; 2018; 106(3):234-241. PubMed ID: 28586782
[TBL] [Abstract][Full Text] [Related]
15. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
[TBL] [Abstract][Full Text] [Related]
16. Recurring Pancreatic Neuroendocrine Tumor: Timing and Pattern of Recurrence and Current Treatment.
Pulvirenti A; Javed AA; Michelakos T; Sekigami Y; Zheng J; Kalvin HL; McIntyre CA; Nebbia M; Chou JF; Gonen M; Raj N; Reidy-Lagunes DL; Zureikat AH; Ferrone CR; He J; Wei AC;
Ann Surg; 2023 Nov; 278(5):e1063-e1067. PubMed ID: 37796750
[TBL] [Abstract][Full Text] [Related]
17. Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas.
Matthews BD; Heniford BT; Reardon PR; Brunicardi FC; Greene FL
Am Surg; 2000 Dec; 66(12):1116-22; discussion 1122-3. PubMed ID: 11149582
[TBL] [Abstract][Full Text] [Related]
18. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors.
Boyar Cetinkaya R; Vatn M; Aabakken L; Bergestuen DS; Thiis-Evensen E
Scand J Gastroenterol; 2014 Jun; 49(6):734-41. PubMed ID: 24679166
[TBL] [Abstract][Full Text] [Related]
19. Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: Limitations to apply guidelines into real life.
Partelli S; Mazza M; Andreasi V; Muffatti F; Crippa S; Tamburrino D; Falconi M
Surgery; 2019 Aug; 166(2):157-163. PubMed ID: 31109657
[TBL] [Abstract][Full Text] [Related]
20. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.
Partelli S; Bertani E; Bartolomei M; Perali C; Muffatti F; Grana CM; Schiavo Lena M; Doglioni C; Crippa S; Fazio N; Zamboni G; Falconi M
Surgery; 2018 Apr; 163(4):761-767. PubMed ID: 29284590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
